Le Lézard
Classified in: Health
Subjects: SVY, AVO, MAT

Regulation Needs to Keep Pace With Global Cannabis Legalisation in 2019 - Prohibition Partners


LONDON, Aug. 22, 2019 /PRNewswire/ -- The number of countries to legalise medical cannabis has risen nine-fold in the last five years, as global attitudes towards cannabis have shifted in favour of liberalisation. In 2019, 43 countries have legalised medical cannabis, with a host more allowing pharmaceutical cannabis. However, international regulatory bodies and treaties lag behind public perception, domestic legislation and patient demand.

The Cannabis Legal Reporttm is the latest industry-leading research from Prohibition Partners, strategic consultants and market intelligence providers for the cannabis industry. The report analyses the current status of legal and regulatory regimes for cannabis around the world. Some key findings include:

Prohibition Partners' Managing Director, Daragh Anglim said: "Regulatory shifts and advances came thick and fast over the last 12 months, such as Thailand's reform of previously conservative cannabis policies, Canada's legalisation of adult-use cannabis and the UK's implementation of a medical cannabis programme. We feel that international regulatory bodies and institutions need to keep pace with global legislative change to offer the clarity that businesses and patients need."

The EU has taken initial steps to develop common standards for medical cannabis - which would go some way to producing clarity in the largest potential cannabis market. The UN, however, has delayed the reclassification of cannabis, which should be a priority according to Prohibition Partners, to better reflect the growing demand and use of cannabis as a medicine. US authorities have been slow to implement new regulations to protect legal cannabis businesses and provide banking security.

Despite this lack of clarity, thousands of patients around the world have been able to access legal medical cannabis in 2019 and Prohibition Partners predicts this growth to gain further momentum at a national level. International regulators will need to follow suit to keep pace with the widening commercial, social and health benefits associated with legal cannabis.

Receive your free copy of the report here: https://prohibitionpartners.com/reports/#the-cannabis-legal-report

The report was published on 22/08/2019, and can also be downloaded on Prohibition Partner's website: www.prohibitionpartners.com   

About Prohibition Partners

We are the world's leading provider of market insights and strategic consultancy for this emerging frontier.

We firmly believe that data, insights and education will unlock the societal and commercial potential of cannabis.

Our research, data and insights are regularly cited by political leaders, investment banks and Fortune 500 companies.

Our consultancy team works with investors, operators and regulators to identify and execute opportunities across multiple jurisdictions. We advise our private clients on licensing, regulatory and business opportunities.

Logo - https://mma.prnewswire.com/media/717815/Prohibition_Partners_Logo.jpg

Prohibition Partners Logo (PRNewsfoto/Prohibition Partners)

 


These press releases may also interest you

at 22:24
Blueprint Medicines Corporation , a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the pricing of an underwritten public offering of 4,710,144 shares of its common stock at a...

at 22:22
"We focus so much on 'sickcare', and we do not focus enough on 'healthcare'. Our mission is to provide more accessible and affordable personal care to the public by using artificial intelligence and data technologies," said Gong Rujing, founder and...

at 22:00
A December 19 article on Business Insider details the importance of dental hygiene in children as young as a few months old, noting that children are just as susceptible to tooth decay as adults. The article recommends using a finger brushing device...

at 21:50
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics ("Zymeworks" or the "Company"), announced today the pricing of its previously-announced underwritten public offering (the "Offering") of 4,924,729...

at 21:20
Co-developers National Community Renaissance (National CORE) and Linc Housing, both California-based nonprofits, today joined Los Angeles County Supervisor Mark Ridley-Thomas, Inglewood Mayor James Butts, Jr., and other partners to celebrate the...

at 20:52
Ascletis Pharma Inc. (Ascletis, 1672.HK) announces today the approval for ASC22 to conduct clinical trials in chronic hepatitis B patients in China from China's National Medical Products Administration. ASC22 is a first-in-class, subcutaneously...



News published on 22 august 2019 at 07:54 and distributed by: